Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis

Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking

MULTIDISCIPLINARY EVALUATION AT BASELINE AND DURING TREATMENT IMPROVES THE RATE OF COMPLIANCE AND EFFICACY OF DEFERASIROX IN ELDERLY MYELODYSPLASTIC PATIENTS

compliance of MDS patients to exjad

Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes

Background Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders, with very different prognosis in given individuals; age and comorbidities are emerging as relevant patient-related factors influencing clinical outcome in MDS. Our aim was to evaluate the impact of age, comorbidities and disease severity (IPSS and IPSS-R prognostic scores) in a \u201creal-life\u201d series of MDS patients. Methods 318 patients with available assessment of comorbidities at diagnosis and consecutively registered into the Registro Ligure delle Mielodisplasie were analyzed. Comorbidities were evaluated according to HCT-CI and MDS-CI comorbidity indexes. Overall survival (OS) and the probability of death among patients who did not develop acute myeloid leukemia (NLD cumulative incidence) were analyzed. Results Comorbidities were seen in 177 (55.7%) patients. An older age (>75 y) had a significant negative impact on OS (p = 0.008). HCT-CI was not associated with OS. MDS-CI was of prognostic significance (p = 0.001), but the association was limited to pts with IPSS or IPSS-R \u201clower-risk\u201d. In multivariate analysis, MDS-CI remained an independent factor associated with OS and with an increased risk of NLD both when controlling for IPSS (p = 0.019 and p = 0.001, respectively) and for IPSS-R (p = 0.048 and p = 0.002, respectively). Conclusions Evaluation of age and comorbidities according to a tailored tool such is MDS-CI helps to predict survival in patients with MDS and should be incorporated to current prognostic scores